MedTrace Logo

Retrospective TMS Therapy for Adults With MDD

NCT05541302 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6456

Last updated 2022-09-15

No results posted yet for this study

Summary

Examine change in the magnitude of antidepressant effects as a function of number of TMS sessions and to determine whether extended treatment courses, beyond 30 and beyond 36 TMS sessions, result in improved efficacy.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DEVICE

TMS

Transcranial Magnetic Stimulation

Sponsors & Collaborators

  • Southern California TMS Center

    collaborator UNKNOWN

  • Brown University

    collaborator OTHER

  • TMS of South Tampa

    collaborator UNKNOWN

  • Sheppard Pratt Health System

    collaborator OTHER

  • Nashville NeuroCare Therapy

    collaborator UNKNOWN

  • NAMSA

    collaborator OTHER

  • Columbia University

    collaborator OTHER

  • Neuronetics

    lead OTHER

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-01
Primary Completion
2022-08-30
Completion
2022-08-31
FDA Device
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05541302 on ClinicalTrials.gov